ELTX Elicio Therapeutics Inc.

Price (delayed)

$1.87

Market cap

$49.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.17

Enterprise value

$39.82M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 7
Highlights
Elicio Therapeutics's EPS has increased by 45% YoY and by 10% from the previous quarter
The net income has increased by 31% year-on-year and by 6% since the previous quarter

Key stats

What are the main financial stats of ELTX

ELTX stock price

How has the Elicio Therapeutics stock price performed over time
Intraday
0%
1 week
5.65%
1 month
-38.49%
1 year
-83.14%
YTD
-76.51%
QTD
-52.17%

Financial performance

How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$37.92M
Net income
-$37.84M
Gross margin
N/A
Net margin
N/A
The net income has increased by 31% year-on-year and by 6% since the previous quarter
The operating income rose by 15% year-on-year

Price vs fundamentals

How does ELTX's price correlate with its fundamentals

Growth

What is Elicio Therapeutics's growth rate over time

Valuation

What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
4.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has increased by 45% YoY and by 10% from the previous quarter

Efficiency

How efficient is Elicio Therapeutics business performance
The ROE has soared by 54% from the previous quarter
ELTX's return on invested capital is up by 21% year-on-year and by 7% since the previous quarter
The company's return on assets rose by 20% YoY and by 7% QoQ

Dividends

What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELTX.

Financial health

How did Elicio Therapeutics financials performed over time
The total assets is 34% greater than the total liabilities
The total assets is up by 38% since the previous quarter and by 6% year-on-year
The current ratio has grown by 24% from the previous quarter and by 21% YoY
ELTX's debt is 78% higher than its equity
Elicio Therapeutics's debt to equity has soared by 118% from the previous quarter but it has plunged by 78% YoY
ELTX's debt is down by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.